New daily persistent headache after SARS-CoV-2 infection: a report of two cases.
COVID-19
Headache
Immunotherapy
Neuroinflammation
Pandemic
Steroid
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
18
04
2021
accepted:
26
06
2021
pubmed:
16
7
2021
medline:
18
9
2021
entrez:
15
7
2021
Statut:
ppublish
Résumé
The 2019 Coronavirus (SARS-CoV-2) is a novel respiratory virus which causes Coronavirus Disease19 (COVID-19). Although the predominant clinical picture of COVID-19 is represented by respiratory symptoms, neurological manifestations are being increasingly recognized. Headache, in particular migraine-like and tension types, has been largely reported in patients suffering from COVID-19 both in the acute and the healing phase of the infection. New daily persistent headache (NDPH) is a primary headache characterized by persistent and daily painful symptoms, with pain becoming continuous and non-remitting within 24 h, and lasting more than 3 months. Even though an increasing number of reports describe patients who develop a persistent headache, diagnosis of NPDH has been rarely explored in the context of COVID-19. Two patients with persistent headache and Sars-CoV-2 infection were identified. Both underwent a full clinical and neuroradiological evaluation. Blood sample with inflammatory biomarkers search was also performed. According to International Classifications of Headache Disorders diagnosis of probable new daily persistent headache was made. The treatment with high doses of steroids was associated with relief of symptoms. Our report described two cases of probable NDPH due to SARS-CoV-2 infection. Clinical evaluation of COVID-19 patients presenting with persistent headache should take into consideration NDPH. Given the supposed major role for neuroinflammation in the genesis of Sars-CoV-2-driven NDPH, immunomodulatory therapy should be promptly started. In line with this hypothesis, we obtained a good therapeutic response to short-term high dose of corticosteroids.
Sections du résumé
BACKGROUND
BACKGROUND
The 2019 Coronavirus (SARS-CoV-2) is a novel respiratory virus which causes Coronavirus Disease19 (COVID-19). Although the predominant clinical picture of COVID-19 is represented by respiratory symptoms, neurological manifestations are being increasingly recognized. Headache, in particular migraine-like and tension types, has been largely reported in patients suffering from COVID-19 both in the acute and the healing phase of the infection. New daily persistent headache (NDPH) is a primary headache characterized by persistent and daily painful symptoms, with pain becoming continuous and non-remitting within 24 h, and lasting more than 3 months. Even though an increasing number of reports describe patients who develop a persistent headache, diagnosis of NPDH has been rarely explored in the context of COVID-19.
METHODS
METHODS
Two patients with persistent headache and Sars-CoV-2 infection were identified. Both underwent a full clinical and neuroradiological evaluation. Blood sample with inflammatory biomarkers search was also performed.
RESULTS
RESULTS
According to International Classifications of Headache Disorders diagnosis of probable new daily persistent headache was made. The treatment with high doses of steroids was associated with relief of symptoms.
CONCLUSIONS
CONCLUSIONS
Our report described two cases of probable NDPH due to SARS-CoV-2 infection. Clinical evaluation of COVID-19 patients presenting with persistent headache should take into consideration NDPH. Given the supposed major role for neuroinflammation in the genesis of Sars-CoV-2-driven NDPH, immunomodulatory therapy should be promptly started. In line with this hypothesis, we obtained a good therapeutic response to short-term high dose of corticosteroids.
Identifiants
pubmed: 34264414
doi: 10.1007/s10072-021-05444-3
pii: 10.1007/s10072-021-05444-3
pmc: PMC8280630
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3965-3968Informations de copyright
© 2021. Fondazione Società Italiana di Neurologia.
Références
Rocha-Filho PAS, Magalhães JE (2020) Headache associated with COVID-19: frequency, characteristics and association with anosmia and ageusia. Cephalalgia 40:1443–1451
doi: 10.1177/0333102420966770
Uygun Ö, Ertaş M, Ekizoğlu E et al (2020) Headache characteristics in COVID-19 pandemic-a survey study. J Headache Pain 21:1–10
doi: 10.1186/s10194-020-01188-1
Yamani N, Olesen J (2019) New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain 20(1):80. https://doi.org/10.1186/s10194-019-1022-z
doi: 10.1186/s10194-019-1022-z
pubmed: 31307396
pmcid: 6734284
Rozen TD (2020) Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: lessons from the 1890 Russian/Asiatic flu. Cephalalgia 40:1406–1409
doi: 10.1177/0333102420965132
Rozen TD (2016) Triggering events and new daily persistent headache: age and gender differences and insights on pathogenesis-a clinic-based study. Headache 56:164–173
doi: 10.1111/head.12707
Rozen T, Swidan SZ (2007) Elevation of CSF tumor necrosis factor α levels in new daily persistent headache and treatment refractory chronic migraine. Headache 47:1050–1055
doi: 10.1111/j.1526-4610.2006.00722.x
Mack KJ (2004) What incites new daily persistent headache in children? Pediatr Neurol 31:122–125
doi: 10.1016/j.pediatrneurol.2004.02.006
Prakash S, Shah ND (2010) Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain 11:59–66
doi: 10.1007/s10194-009-0171-x